A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates

Marie L. Landry, Sylvia Stanat, Karen Biron, Donald Brambilla, William Britt, Janet Jokela, Sunwen Chou, W. Lawrence Drew, Alejo Erice, Bruce Gilliam, Nell Lurain, Jody Manischewitz, Richard Miner, Mostafa Nokta, Patricia Reichelderfer, Stephen Spector, Adriana Weinberg, Belinda Yen-Lieberman, Clyde Crumpacker

Research output: Contribution to journalArticle

98 Scopus citations

Abstract

Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cytomegalovirus (CMV) cell-associated clinical isolates. Four characterized and plaque-purified CMV strains, as well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two isolates. Analysis of these results indicates the problems associated with clinical isolates, including the large genetic variability and the highly cell- associated phenotype. This collaborative effort, by addressing these problems, represents a significant step toward the development of a standardized assay.

Original languageEnglish (US)
Pages (from-to)688-692
Number of pages5
JournalAntimicrobial agents and chemotherapy
Volume44
Issue number3
DOIs
StatePublished - Mar 1 2000

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Landry, M. L., Stanat, S., Biron, K., Brambilla, D., Britt, W., Jokela, J., Chou, S., Drew, W. L., Erice, A., Gilliam, B., Lurain, N., Manischewitz, J., Miner, R., Nokta, M., Reichelderfer, P., Spector, S., Weinberg, A., Yen-Lieberman, B., & Crumpacker, C. (2000). A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrobial agents and chemotherapy, 44(3), 688-692. https://doi.org/10.1128/AAC.44.3.688-692.2000